Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Lp(a) Gene Variant Association

Reporter: Larry H Bernstein, MD, FCAP

Lp(a) Gene Variant Associated With Aortic Stenosis

Reported by Lisa Nainggolan Feb 06, 2013; GThanassoulis et al. NEJM http://www.theheart.org/article/1503525.do

People carrying this single nucleotide polymorphism (SNP) had a doubling of the risk of valve calcification on computer tomography (CT) compared with those without the variation. The same SNP has previously been identified as a risk factor for increased Lp(a) levels and coronary artery disease (CAD). Findings Could Reawaken Interest in Therapies Targeting Lp(a)

Related articles

• Genetic Study Identifies Strong Links To Aortic Valve Disease (forbes.com)
• Researchers Find Gene Variant Linked To Aortic Valve Disease (medicalnewstoday.com)
• MGH’s Largest-ever Genetic Study of Five Psychiatric Disorders: Variation in SNPs in Two Genes involved in Calcium-Channel Signaling (pharmaceuticalintelligence.com)
• Link Between Most Common Form Of Heart Valve Disease And Unusual Cholesterol (medicalnewstoday.com)

A Single Nucleotide Polymorphism is a change of a nucleotide at a single base-pair location on DNA. Created using Inkscape v0.45.1. (Photo credit: Wikipedia)

 

0.000000 0.000000

Share this:

• Twitter
• Facebook
• LinkedIn
• Print
• Email

Like this:

Like Loading...

Related

Posted in Cardiovascular Pharmacogenomics, Genome Biology, Genomic Testing: Methodology for Diagnosis, International Global Work in Pharmaceutical, Pharmacotherapy of Cardiovascular Disease | Tagged Aortic valve stenosis, Coronary artery disease, Genome-wide association study, health, Lipoprotein, New England Journal of Medicine, Risk factor, Single-nucleotide polymorphism, The New England Journal of Medicine, X-ray computed tomography | 6 Comments

6 Responses

1. on March 7, 2013 at 1:14 AM | Reply Lp(a) Gene Variant Association | Pharmaceutical Intelligence | Neuro Physiology Blog

   […] View article: Lp(a) Gene Variant Association | Pharmaceutical Intelligence […]

   
   
2. on April 14, 2013 at 2:04 PM | Reply Reversal of cardiac mitochondrial dysfunction | Pharmaceutical Intelligence

   […] Lp(a) Gene Variant Association (pharmaceuticalintelligence.com) […]

   
   
3. on April 14, 2013 at 5:48 PM | Reply Mitochondrial dysfunction and cardiac disorders | Pharmaceutical Intelligence

   […] Lp(a) Gene Variant Association (pharmaceuticalintelligence.com) […]

   
   
4. on April 14, 2013 at 8:28 PM | Reply Mitochondrial metabolism and cardiac function | Pharmaceutical Intelligence

   […] Lp(a) Gene Variant Association (pharmaceuticalintelligence.com) […]

   
   
5. on April 15, 2013 at 10:33 AM | Reply CHAPTER 5. Mitochondria and Cardiovascular Disease | Pharmaceutical Intelligence

   […] Lp(a) Gene Variant Association (pharmaceuticalintelligence.com) […]

   
   
6. on January 29, 2014 at 3:56 PM | Reply Voices from the Cleveland Clinic On Circulating apoA1: A Biomarker for a Proatherogenic Process in the Artery Wall | Pharmaceutical Intelligence

   […] https://pharmaceuticalintelligence.com/2013/03/06/10447/ […]

   
   

Leave a Reply Cancel reply

Enter your comment here...

Fill in your details below or click an icon to log in:

Email (required) (Address never made public)

Name (required)

Website

You are commenting using your WordPress.com account. ( Log Out /  Change )

You are commenting using your Google account. ( Log Out /  Change )

You are commenting using your Twitter account. ( Log Out /  Change )

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s

Notify me of new comments via email.

Notify me of new posts via email.